LIDOCAINE
Carpal Tunnel Syndrome
Haydarpasa Numune Training and Research HospitalSmall moleculePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 58/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Carpal Tunnel Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
IBUPROFEN Universidad Europea de Madrid | Phase 4 | BB |
VITAMIN D Dr. Ayşe Güç | Phase 4 | BB |
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)- Endo USA Inc., a Keenova Therapeutics Company | Phase 4 | BB |
Bont-A Francesco Bono | Phase 2 | CCC |
EVUZAMITIDE University of Tennessee Graduate School of Medicine | Phase 2 | CCC |
View all 11 →
Same molecule, other indications
LIDOCAINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →